The qDBS technology of Capitainer® was recently shown to significantly improve monitoring for PKU positive patients in the study “Evaluation of volumetric blood collection devices for the measurement of phenylalanine and tyrosine to monitor patients with phenylketonuria” conducted by Rachel S. Carling a b, Erin C. Emmett b, Stuart J. Moat.
A recent evaluation by Professor Stuart Moat and Rowan Hellier, who kindly provided their data, has again shown the benefits of Capitainer® technology versus standard DBS in another genetic disorder, congenital adrenal hyperplasia (CAH)*. 17-OHP is a hormone made by the adrenal glands and a 17-OHP analysis test measuring this concentration helps monitor this disorder.
The study showed that in 17-OHP analysis, the CV% were improved from 14,1% down to 3,4% when comparing standard DBS with a 6mm punch and the Capitainer®B sampling card. The precision was also better with the qDBS technology than with pipetting 10µL of blood, data that was also shown in the PKU monitoring publication.
This is another example of how the Capitainer® solution can improve diagnostic solutions.
Check out the linked poster for more information.
Get in touch with us if you want to learn more.
*The experiments were performed at Medical Biochemistry, University Hospital of Wales, Cardiff, UK.